Market

In a groundbreaking development, the recent trials of a drug developed by Ireland-based psychedelics biotech company GH Research have showcased its potential in treating treatment-resistant depression. The mid-stage clinical trial, comprising 81 participants, revealed a significant reduction in

The cell culture media market is experiencing a significant surge, driven by technological advancements and increased investments in research and development (R&D). These media are crucial for the growth, proliferation, and maintenance of various cell types, including microbial cells and stem

The biotech and healthcare sectors in the United Kingdom experienced a remarkable year in 2024, marked by substantial financial investments, significant trends, and notable challenges. Grounded in a report by the UK BioIndustry Association (BIA), this analysis delves into the pivotal investment

In a surprising move, Rentschler Biopharma announced its decision to withdraw from the cell and gene therapy (CGT) business at its Stevenage, UK facility, marking a significant shift in the company's strategic focus. This decision comes despite recent investments in building advanced

10x Genomics, under the leadership of co-founder and CEO Serge Saxonov, PhD, is making a strategic shift towards enhancing customer support and expanding its presence in the biopharma market. Following a prolific year of product launches in 2024, the company is now focusing on promoting its recent

On Thursday, the Food and Drug Administration approved Journavx, a highly anticipated non-opioid pain medication developed by Vertex Pharmaceuticals, marking a significant milestone in the effort to shift pain treatment away from opioids. This new drug has been initially approved to treat acute